Where does Alnylam Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Alnylam Pharmaceuticals, Inc. ranks #1,451 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Alnylam Pharmaceuticals, Inc. hold?

Alnylam Pharmaceuticals, Inc. holds 287 US utility patents granted between 2015 and 2025, spanning 23 technology areas.

What is Alnylam Pharmaceuticals, Inc.'s Innovation Score?

Alnylam Pharmaceuticals, Inc. has an Innovation Score of 56.4 out of 100 (top 6% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Alnylam Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Alnylam Pharmaceuticals, Inc.'s recent grant velocity is +2% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Alnylam Pharmaceuticals, Inc.'s patents?

Alnylam Pharmaceuticals, Inc.'s patents average 26.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Alnylam Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Alnylam Pharmaceuticals, Inc.

Q: What technology areas does Alnylam Pharmaceuticals, Inc. focus on?

Alnylam Pharmaceuticals, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 262 patents, ranking #19 of 4,144 assignees active in that subclass. Grants appear in 23 CPC subclasses total.

USPTO PatentsView assignee record - 287 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Alnylam ranks #1,451 of 49,997 tracked US assignees by granted-patent volume, with 287 patents across 23 technology areas.

#1,451
of 49,997 US assignees by volume: Top 6%
by Innovation Score (56.4/100): 26.0
avg claims per patent: +2%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1451 · US Corporation #1,451 · 287 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 287 grants
TOP-DECILE #1,451/49,997
PHOTO-FINISH Carl Freudenberg KG
CPC-FOCUS C12N · 23 areas
INNOV-PAR 56.4/100
CLAIMS-DENSE 26.0 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +2% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Carl Freudenberg KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Alnylam’s 56.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 19.6 pts (35%) Velocity 4.9 pts (9%) Breadth 17.0 pts (30%) Claim depth 15.0 pts (27%)

Qualcomm Incorporated · highest

85
Alnylam Pharmaceutic… · this assignee

56
Hollister Incorporated · near

56
Micro Focus · near

56
Miltenyi Biotec B V… · near

56
Rovi Product · near

56
3D Lighting… · lowest

7

What this shows Alnylam's Innovation Score is 56.4/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Alnylam?

Each dot is one of Alnylam’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Alnylam’s own 26.0 claims/patent is ABOVE the 12.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Alnylam vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Alnylam's grants concentrate

Alnylam Pharmaceuticals, Inc. is a focused PatentsView assignee: 23 CPC subclasses with 91.3% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2015 (42 grants) versus a trough of 17 in 2017. By volume, Alnylam sits between Julius Blum GMBH and Jiaxing Super Lighting Electric Appliance Co., Ltd.

Alnylam's three-year grant acceleration

From 2019–2021 to 2022–2024, Alnylam Pharmaceuticals, Inc. moved from 93 to 68 grants (0.73x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,046. See the growth leaderboard.

Julius Blum

288
Milliken &

288
National Institut…

288
Nifco

288
Carl Freudenberg…

287
EMD Millipore

287
Tyco Fire Products

287
Alnylam Pharmaceu… ◀

287
Jiaxing Super Lig…

286

What this shows Alnylam holds 287 patents at rank #1,451, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Alnylam

By rank, the assignees closest to #1,451 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Alnylam's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Alnylam, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Alnylam ranks #19 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (56 here).

Hollister Incorporated 56 Micro Focus LLC 56 Miltenyi Biotec B.V. & Co. KG 56 Rovi Product Corporation 56

Similar claim depth

Nearest assignees by average claims per patent (26.0 here).

Novozymes, Inc. 26.0 avg Omya International AG 26.0 avg Incyte Corporation 26.1 avg CompoSecure, LLC 26.0 avg

Alnylam's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Alnylam Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	42	14.6%
2016	24	8.4%
2017	17	5.9%
2018	22	7.7%
2019	27	9.4%
2020	25	8.7%
2021	41	14.3%
2022	26	9.1%
2023	18	6.3%
2024	24	8.4%
2025partial year	21	7.3%

Which technologies does Alnylam Pharmaceuticals, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 262

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 210

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 202

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 56

C12Y - Enzymes 32

Y02A - Technologies FOR Adaptation TO Climate Change 25

C07C - Acyclic OR Carbocyclic Compounds 24

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 24

C07D - Heterocyclic Compounds 23

C07K - Peptides 17

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 10

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

Top 15 of 23 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Alnylam Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Alnylam Pharmaceuticals, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 91.3% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #1,451 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Alnylam Pharmaceuticals, Inc. against Julius Blum GMBH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 56.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.